SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
Valuation | |
---|---|
Market Cap ($M) | 114,793.55 |
Enterprise Value ($M) | 135,893.55 |
Book Value ($M) | 18,390.00 |
Book Value / Share | 14.76 |
Price / Book | 6.24 |
NCAV ($M) | -23,076.00 |
NCAV / Share | -18.52 |
Price / NCAV | -4.97 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.00 |
Return on Assets (ROA) | 0.00 |
Return on Equity (ROE) | 0.01 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.82 |
Current Ratio | 1.11 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 13,059.00 |
Assets | 54,525.00 |
Liabilities | 36,135.00 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Vanguard Group Inc | 8.97 | -0.19 | |
13G/A | Capital World Investors | 6.70 | 21.48 | |
13G/A | BlackRock, Inc. | 9.90 | -6.66 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
957,593 | 7,699,976 | 12.44 | |
561,077 | 5,640,419 | 9.95 | |
899,387 | 7,758,480 | 11.59 | |
464,304 | 6,522,882 | 7.12 | |
(click for more detail) |
Similar Companies | |
---|---|
FGEN – FibroGen, Inc. | GBIO – Generation Bio Co. |
GERN – Geron Corporation | GLUE – Monte Rosa Therapeutics, Inc. |
GOSS – Gossamer Bio, Inc. |